Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CCNC | P24863 | 8/20 | 0.56 |
| ▸ | CDK8 | P49336 | 8/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210771 | 0.95 | HPGD (0.53) | SIGMAR1CCNCCDK8MKNK1MKNK2 | |
| SCHEMBL3224806 | 0.84 | MEN1 (0.71) | MAPK1POLB | |
| SCHEMBL5266293 | 0.83 | SIGMAR1 (0.80) | SIGMAR1CCNCCDK8MKNK1MKNK2 | |
| SCHEMBL3221724 | 0.82 | POLB (0.49) | HPGDMAPK1GHSRPOLB | |
| Hydrochloric Acid SCHEMBL4763940 | 0.82 | SIGMAR1 (0.77) | SIGMAR1CCNCCDK8MKNK1MKNK2 | |
| SCHEMBL3218607 | 0.80 | HPGD (0.52) | HPGDMAPK1GHSRPOLB | |
| SCHEMBL3218307 | 0.80 | SMN1; SMN2 (0.51) | HPGDMAPK1 | |
| SCHEMBL13295295 | 0.79 | HPGD (0.73) | SIGMAR1HPGDRXFP1POLB | |
| SCHEMBL774880 | 0.78 | KDM1A (0.57) | — | |
| Piperazine SCHEMBL27980519 | 0.78 | HPGD (0.71) | SIGMAR1HPGDRXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | SIGMAR1 4510/4885CCNC 124/4885CDK8 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.